The World Health Organization (WHO) defines adverse drug reactions (ADR) as "response to a drug that is noxious and unintended and occurs at doses normally used in men for prophylaxis, diagnosis or therapy of disease, or for modification of physiological function" [1] . Reactions can be caused by any therapeutic agent, such as antibiotics, analgesics, blood products, vaccines or radiographic contrast media [2] . The reaction may be a well-known side effect of the drug or an undefined new reaction. Initially, many ADRs are unpredictable; they are mostly described after the post-marketing widespread usage [2] . Age, polypharmacy and additional diseases are the main risk factors for ADRs [3] . A study by Pirmohamed et al. [4] showed that patients admitted with ADRs were significantly older than patients without ADRs (76 versus 66 years). Therefore, ADRs pose a considerable burden among hospitalized patients who are more likely to be older and taking multiple medicines. ADRs are more common than expected among hospitalized patients; they may occur in up to 16.8% of patients during hospitalization, and 16% of these reactions may be fatal [5, 6] .
Adverse drug reactions are regularly recorded at our inpatient settings using ADR reporting forms, which are filled by nurses. The rate of ADR reporting has nearly quadrupled over eight years ( Figure 2 ). Between 2016 and 2017, ADRs were observed in 65 of 14,347 hospitalized patients. The mean age of the patients was 49.2±19.4 years; 69% of all patients were female. Four of these patients were children, whereas the others were adults. There were no ADR-related deaths.
Turk Thorac J 2018; 19(4) : 237-9 At our hospital, the ADR rate was particularly high in the elderly and patients receiving cancer treatment. The mean age of patients receiving cancer treatments was 56.1±14.6 years. Forty-seven reports were received from the adult oncology department. Seventeen of them had hematologic, 10 had urogenital, and 7 had gastrointestinal system malignancies. Eight patients had breast cancer, 3 had lung cancer, and 2 had other diseases. Nine patients had drug allergy and 2 had respiratory allergy history who reported ADRs. Chemotherapeutic and biologic administrations were mostly related to ADRs. Taxol and platinum salts were the most commonly used chemotherapeutic drugs; Rituximab was the most common among biologics. All reactions were allergic ranging from mild to severe. Five of these patients had tryptase results. After discussing the annual results of 2016-2017 at the ADR team meeting, we planned and realized two additional anaphylaxis management educations for nurses and healthcare professionals. We also discussed our results with the oncology team to provide effective management after chemotherapy and biological agent allergy, such as desensitization.
The routine use of ADR reporting forms increased the chemotherapeutic and biological drug allergy awareness at our hospital. Our inpatient nurses are now more aware of their responsibility to report ADRs and how to report them. Clinicians are now more aware of both the common occurrence of ADRs and their responsibility to manage them. We require greater use of such documentation in hospitals in Turkey. Therefore, improving reporting rates of ADRs would decrease the ADRrelated mortality rates in hospitalized patients, particularly in the elderly population. This reporting system can only be successful if used more widely in hospitals. We should discover the potentials gaps for reporting ADRs in hospitals and find answers to improve the awareness of ADRs in hospital settings.
In conclusion, ADRs are common among hospitalized patients and may be severe. Older patients and the ones taking chemotherapeutic and biological drugs are more prone to ADRs. Additionally, allergic reactions occupy a significant place among all ADRs. The contribution of nurses and clinicians is essential to increase good pharmacovigilance practices. The routine use of the ADR reporting system is easy and inexpensive and may largely impact the safety and quality of patient-centered health care delivery. 
